Kuros Biosciences Reports Results for First Half 2019

Schlieren (Zurich), Switzerland, August 20, 2019 – Kuros Biosciences, a leader in next generation bone graft technologies, today reported its results for the first half year 2019. The Company accelerated product sales in the first half of 2019, while further decreasing administrative expenses, confirming its successful transition into a full-fledged...

read more

Neurimmune and REGENXBIO Announce Collaboration to Develop Vectorized Antibodies for the Treatment of Neurodegenerative Diseases

Zurich, Switzerland and Rockville, MD, July 24, 2019 -- Neurimmune AG, a leading clinical-stage Swiss biotech company translating human immune memory into antibody therapeutics and REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV®...

read more

Positive MAPLE data for abicipar, promising research data for Molecular Partners’ innovative oncology DARPin® candidates presented; Recruitment hold in MP0250 NSCLC trial; Ongoing focus on multiple myeloma for MP0250 clinical development

Zurich-Schlieren, May 9, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, announced today its Interim Management Statement for the period ending March 31, 2019. “Our team is focused on delivering on our strategic priorities by advancing clinical candidates MP0250 and...

read more